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showed no significant change in these variables, but rather 
reported stable higher psychopathology. Similar results 
were found on a subclinical level in siblings. Patients with 
co-occurring OCS present a more severe clinical picture, 
especially if symptoms persist over time. The remission of 
OCS was associated with overall improvement, whereas 
individuals with de novo OCS already reported higher clin-
ical impairment before OCS onset. More research is needed 
to elucidate causal pathways and to develop effective inter-
ventions for persistent comorbid OCS.
Keywords Psychosis · Schizophrenia · Obsessive–
compulsive · Comorbidity · Longitudinal
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Introduction
Recent meta-analyses conclude that 12% of patients with 
schizophrenia also fulfil the criteria for obsessive–compulsive 
disorder (OCD) and that about 30% report obsessive, dis-
tressing, intrusive thoughts and related compulsions [1–3]. A 
recent longitudinal cohort study in Sweden showed that indi-
viduals with OCD had an increased risk of late diagnosis of 
schizophrenia and vice versa [4]. Hence, the co-occurrence of 
OCD and psychotic disorders is a common problem, which 
has led to an increased research interest over the last decade.
The question how co-occurring obsessive–compulsive 
symptoms (OCS) interact with other clinical characteris-
tics in schizophrenia patients led to conflicting findings. 
Abstract The course of obsessive–compulsive symptoms 
(OCS) and its association with alterations in other clini-
cal variables in patients with psychotic disorders is insuf-
ficiently known. Patients (n = 602) and unaffected siblings 
(n = 652) from the Dutch Genetic Risk and Outcome of 
Psychosis (GROUP) study were investigated at base-
line and after 3 years. Participants were assigned to four 
groups based on the course of OCS over time: no-OCS, 
persistent OCS, initial OCS and de novo OCS. In addition 
to cross-sectional comparisons, longitudinal associations 
between changes in OCS and symptoms of schizophrenia 
and general functioning were investigated. Patients with 
co-occurring OCS reported significantly higher severity of 
psychotic and affective symptoms as well as lower overall 
functioning compared to patients without OCS. These dif-
ferences were stable over time for patients reporting persis-
tent OCS. Subsequent repeated measure analysis revealed 
significant interaction effects for groups reporting changes 
in their OCS. Whereas the group with remission of initial 
OCS showed significant improvement in positive symp-
toms, emotional distress and functioning, the de novo group 
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Early concepts hypothesized that patients with schizophre-
nia develop OCS in an attempt to reduce psychotic symp-
toms, and thus, the presence of OCS was thought to have a 
protective effect regarding psychotic disintegration [5, 6]. 
Subsequent research which investigated the clinical effect 
of comorbid OCS in schizophrenia showed greater levels of 
hopelessness [7], lower quality of life [8], more social dys-
function [9, 10] and a higher degree of cognitive impair-
ment [11, 12]. Consequently, patients with schizophrenia 
and comorbid OCS were reported to have a less favourable 
prognosis [13–17]. Regarding the relationship between 
OCS and severity of schizophrenia symptoms, findings 
yielded inconclusive and to some degree contradictory 
results [18]. A meta-analysis by Cunill et al. [14] concluded 
that most studies reported more severe positive, and nega-
tive symptoms if OCS were present. However, several stud-
ies did not find significant associations [10, 19–21], and 
others even reported lower severity of negative symptoms 
[22] or lower levels of positive and negative symptoms in 
patients with a first psychotic episode and comorbid OCS 
[23, 24]. A finding that has consistently been replicated is 
the association between comorbid OCS and more severe 
depressive symptoms [10, 24–27].
So far, research assessing the association between co-
occurring OCS, affective and psychotic symptoms has 
mainly been investigated in cross-sectional designs. Group 
comparisons are therefore often restricted to the presence or 
absence of OCS at one single assessment time. Fontenelle 
et al. [28] investigated OCD in a cohort of individuals at 
ultra-high risk of psychosis and found especially persis-
tent OCD related to the development of a psychotic disor-
der 7 years later. Another recent prospective study investi-
gated the 5-year course of OCS in a sample of first-episode 
patients. de Haan et al. [10] found no differences in positive 
and negative symptoms between patients with versus with-
out OCS at any of the three assessments, nor did the pres-
ence of initial OCS predict time to relapse or symptomatic 
recovery 5 years later. To the best of our knowledge, so far 
no study has investigated the course of OCS and associated 
changes in the severity of schizophrenia symptoms over 
time. Furthermore, nothing is known about the course of 
OCS and its relation with subclinical psychotic and depres-
sive symptoms in relatives of patients with a psychotic 
disorder. Research in unaffected family members offers a 
unique possibility to study associations between changes in 
OCS and alterations in subclinical symptoms without con-
founding therapy-related factors.
The aim of the present study was to investigate the lon-
gitudinal course of co-occurring OCS and its relationship 
with psychotic symptoms, affective symptoms and social 
functioning in a large cohort of patients with psychotic 
disorders. In addition, associations between OCS and sub-
clinical symptoms in a cohort of unaffected siblings were 
investigated as a unique validation approach. Based on the 
above-reported literature, we hypothesize that persistent 
comorbid OCS are related to more severe symptoms of 
schizophrenia and depression and to more severe functional 
impairment. We further propose that the de novo develop-
ment of OCS is associated with an increased severity of 
these clinical variables, whereas remission of initial OCS is 
associated with a decreased severity.
Methods
Study design and participants
The study sample was part of the multicenter study 
‘Genetic Risk and Outcome of Psychosis’ (GROUP). Base-
line and 3-year follow-up assessments of patients and sib-
lings with complete data sets were included in the study. 
The procedure of recruitment and population characteris-
tics have been described in detail elsewhere [29]. In short, 
inclusion criteria for patients and siblings were (1) age 
range of 16–50 years and (2) good command of the Dutch 
language. Patients had to meet DSM-IV-TR criteria for a 
non-affective psychotic disorder [30] which was assessed 
with the Comprehensive Assessment of Symptoms and 
History (CASH [31]) or the Schedules for Clinical Assess-
ment for Neuropsychiatry version 2.1 (SCAN [32]). An 
additional inclusion criterion for the sibling group was the 
absence of a lifetime psychotic disorder. All participants 
provided written informed consent prior to their inclusion 
in the study, which was approved by the accredited Medical 
Ethics Review Committee (METC).
Clinical measures
Sociodemographic data on age, gender, education level, 
age of onset, duration of illness and medical treatment were 
collected. Current diagnosis of cannabis abuse and depend-
ence was assessed using the Composite International Diag-
nostic Interview (CIDI [33]). Severity of OCS was meas-
ured with the Yale–Brown Obsessive–Compulsive Scale 
(YBOCS [34]), which has been validated for the assess-
ment of OCS in schizophrenia [35, 36]. Severity of positive 
and negative symptoms and emotional distress in patients 
was assessed with the Positive and Negative Syndrome 
Scale (PANSS [37]) according to the five-factor model 
(positive subscale: P1, P3, P5, P6, G9; negative subscale: 
N1, N2, N3, N4, N6, G7, G8, G16; and emotional distress: 
G2, G3, G4, G6) [38]. The Community Assessment of 
Psychic Experiences (CAPE [39]) is a 42-item self-report 
questionnaire, which was used to assess frequency and 
associated distress with mild psychotic experiences in sib-
lings. Three subscales cover positive psychotic experiences, 
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negative psychotic experiences and depressive feelings. In 
the current study, only frequency ratings were included as 
outcome measure. Social functioning was measured using 
the Global Assessment of Functioning Scale (GAF [40]) 
with separate ratings for symptoms and degree of disability 
[41]. Before the start of the study, all interviewers received 
extensive training workshops to practise the assessments 
of all measures used in the GROUP project (for details see 
[29]).
Statistical analysis
Statistical analyses were performed using the Statistical 
Package for Social Sciences (SPSS version 18.0, Chicago, 
IL, US). Sociodemographic and psychopathological char-
acteristics were compared between the groups using multi-
variate analysis of variance (MANOVA) and χ2 tests.
Fixed-effect regression models were used for PANSS/
CAPE and GAF outcome measures with the different OCS 
groups (no-OCS, persistent, remission or de novo) as the 
fixed part of the model and covariates to account for sig-
nificant between-group differences in medical history in 
patients. These models were separately analysed for the two 
status groups (patients and unaffected siblings) at baseline 
and follow-up. Bonferroni corrections for multiple compar-
isons were applied for subsequent pairwise analyses.
To assess longitudinal changes in clinical characteris-
tics over time, we calculated repeated measure analysis of 
variances (rmANOVAs) and post hoc paired t test with the 
OCS group as the fixed part of the model and psychopa-
thology and functioning as the dependent variables. These 
models were analysed separately within the factor stability 
(no changes vs. changes in reported OCS) and the two sta-
tus groups (patients and siblings). Effect sizes were calcu-
lated to complement statistical significance of within-group 
changes (Cohen’s dz) and to give an estimation of small 
(dz = 0.2), medium (dz = 0.5) or large (dz = 0.8) effects. 
Correlation analyses assessed the association between 
changes in the severity of OCS and other clinical variables.
Results
Sociodemographic characteristics and clinical 
assessments
We included 602 patients and 652 siblings in our analy-
ses with complete data of sociodemography, YBOCS and 
PANSS/CAPE scores for both assessments. Based on 
interpretation guidelines, we defined the presence of OCS 
as a YBOCS total score of at least 8, representing mild 
symptom severity [34]. 31.0% of patients and 7.8% of sib-
lings fulfilled this criterion at least at one assessment. The 
majority of participants reported changes in their comor-
bid OCS between assessments either as newly occurring 
de novo OCS (12.0%) or as remission of initially reported 
OCS (11.6%); only 7.5% reported persistent OCS over 
time. Therefore, we created the following groups within 
the patient sample: OCS de novo (n = 72): development of 
at least mild OCS at follow-up; OCS remission (n = 70): 
remission of initially reported OCS at follow-up; persis-
tent OCS (n = 45): at least mild OCS at both assessment 
times; and no-OCS group (n = 415): no relevant OCS at 
either time point. Accordingly, unaffected siblings were 
assigned to a de novo OCS group (n = 25), OCS remission 
group (n = 26) or no-OCS group (601). Because only five 
siblings presented persistent OCS, we did not include this 
group in our main analyses.
Table 1 presents between-group comparisons on demo-
graphic and clinical variables. The four patient groups did 
not significantly differ in age, gender, ethnicity, education, 
diagnosis, current cannabis abuse/dependence or estimated 
total IQ. Patients in the remission group showed a trend 
towards an earlier age at onset when compared to the no-
OCS group [mean difference (md = 2.1446, p = .054)], 
and the persistent group reported longer illness duration 
compared to the no-OCS group (md = 1.643, p = .028). 
Comparisons within siblings did not reveal any significant 
group differences (Table 1). According to group definition, 
baseline and follow-up assessment of OCS severity differed 
between the above-defined groups (Table 1).
Regarding current intake of medication, data on current 
use of antipsychotic and antidepressive medication were 
available in a subsample of 369 patients. The number of 
patients treated with clozapine compared to all other antip-
sychotic medication did not significantly differ at base-
line, but reached significance at follow-up (χ2 = 10.264, 
p = .016). Post hoc comparisons revealed that significantly 
more patients in the de novo (χ2 = 4.167, p = .041) and 
persistent (χ2 = 7.782, p = .005) group received CLZ com-
pared to the no-OCS group.
Comparisons on the frequency of antidepressant treat-
ment revealed significant between-group differences at fol-
low-up (χ2 = 22.582, p < .001). Post hoc pairwise compari-
sons showed that the de novo group and persistent group 
were more frequently treated with antidepressants than 
the no-OCS group (χ2 = 10.213, p = .001; χ2 = 17.623, 
p < .001) and patients in the persistent group were also 
more likely to be treated with antidepressants than in the 
remission group (χ2 = 4.271, p = .039).
Although numbers were small, in an explorative 
approach, we assessed whether the risk for siblings to pre-
sent with OCS at baseline or follow-up was greater for 
those siblings of patients, who report OCS at least once 
during the assessment period. Relative risk calculations 
were done in a subsample of 467 patient–sibling pairs from 
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the same families. Compared to siblings of patients of the 
no-OCS group, siblings of patients of the initial persistent 
or de novo group did not show significantly increased rela-
tive risks to report OCS at baseline or follow-up. For more 
details, see Table 1 in supplementary material.
Cross‑sectional between‑group differences at baseline 
and follow‑up
To assess between-group differences at baseline and fol-
low-up in patients, multivariate analyses of variance were 
calculated. To account for differences in age at onset and 
illness duration, these variables were added as covariates 
to the models. Analyses revealed significant results for all 
PANSS and GAF scores at both assessments except for a 
non-significant trend for the PANSS negative subscale at 
follow-up (Table 2). Post hoc pairwise analyses showed 
significantly higher PANSS positive and emotional distress 
scores, as well as lower GAF symptom scores for the three 
groups with persistent (md = 4.16, p < .001; md = 4.46, 
p < .001; md = 7.32, p = .023), remission (md = 2.92, 
p = .001, md = 3.58, p = <.001; md = 7.56, p = .002) and 
de novo OCS (md = 2.44, p = 002; md = 2.41, p = .003; 
md = 4.18, p = .046) when compared to the no-OCS group 
at baseline. The persistent group also showed significantly 
higher PANSS negative and lower GAF disability scores 
Table 1  Sociodemographic and clinical characteristics in patients and siblings at baseline
OCS obsessive–compulsive symptoms, WAIS Wechsler Adult Intelligence Scale, YBOCS Yale–Brown Obsessive–Compulsive Scale
Patients OCS de novo OCS remission Persistent OCS No-OCS Between-group differences
N = 72 N = 70 N = 45 N = 415
 Age 26.9 ± 5.8 25.6 ± 6.5 27.2 ± 6.0 27.4 ± 7.4 F3,598 = 1.380, p = .248
 Gender (male/female) 58/14 55/15 36/9 319/96 χ2 = 0.673, p = .879
 Ethnicity (Caucasian/others) 58/14 57/13 35/10 347/68 χ2 = 1.298, p = .730
 Age of onset 21.9 ± 5.4 21.2 ± 6.1 21.4 ± 6.2 23.3 ± 6.5 F3,598 = 3.709, p = .012
 Duration of illness 4.9 ± 3.8 4.4 ± 3.3 5.8 ± 4.2 4.2 ± 3.7 F3,598 = 3.289, p = .020
 Education in years 13.0 ± 3.6 12.8 ± 4.0 12.3 ± 4.8 12.6 ± 3.7 F3,581 = 0.352, p = .788
 WAIS estimated total IQ 93.8 ± 14.2 95.7 ± 15.2 94.7 ± 15.9 97.3 ± 16.5 F3,574 = 1.097, p = .350
 Cannabis abuse/dependence (yes/no) 16/56 17/53 4/41 76/339 χ2 = 4.898, p = .179
Diagnosis
 Schizophrenia 53 48 35 259 χ2 = 16.727, p = .335
 Schizophreniform disorder 1 4 2 34
 Schizoaffective disorder 10 11 6 61
 Delusion disorder 1 0 0 11
 Brief psychotic episode 0 0 1 10
 Psychotic disorder NOS 7 7 1 40
YBOCS
 Obsessions 0.5 ± 1.4 6.7 ± 4.6 6.5 ± 5.2 0.1 ± 0.7
 Compulsions 0.3 ± 1.1 6.1 ± 4.8 7.4 ± 4.6 0.1 ± 0.5
 Total 0.8 ± 1.7 12.8 ± 5.6 13.8 ± 6.0 0.2 ± 0.8
Siblings OCS de novo OCS remission No-OCS Between-group differ-
encesN = 25 N = 26 N = 601
 Age 28.2 ± 8.4 27.6 ± 9.0 27.8 ± 8.0 F2,649 = 0.036, p = .965
 Gender (male/female) 8/17 8/18 276/325 χ2 = 3.993, p = .136
 Ethnicity (Caucasian/others) 23/2 24/2 522/79 χ2 = 1.182, p = .554
 Education in years 14.8 ± 3.6 14.5 ± 4.6 13.8 ± 3.7 F2,637 = 1.360, p = .258
 WAIS estimated total IQ 99.0 ± 17.5 102.8 ± 15.8 104.5 ± 15.6 F2,637 = 1.517, p = .220
 Cannabis abuse/dependence (yes/no) 1/24 3/23 28/573 χ2 = 2.786, p = .426
YBOCS
 Obsessions 0.0 ± 0.2 3.7 ± 4.3 0.0 ± 0.2
 Compulsions 0.4 ± 1.4 6.1 ± 3.4 0.1 ± 0.6
 Total 0.5 ± 1.4 9.8 ± 4.9 0.1 ± 0.7
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compared to the no-OCS group (md = 3.36, p = .004; 
md = 9.09, p = .001).
Three years later, the persistent group still showed sig-
nificantly more impairment compared to the no-OCS group 
(PANSS positive: md = 4.58, p < .001; emotional dis-
tress: md = 5.21, p < .001; GAF symptoms: md = 11.12, 
p = <.001; and GAF distress: md = 13.29, p < .001) and 
higher PANSS positive and lower GAF disability scores 
(md = 3.56, p = .006; md = 11.30, p = 001) compared 
to the remission group. Accordingly, the de novo group 
reported significantly higher scores compared to the no-
OCS group on measures of positive symptoms (md = 3.54, 
p < .001), emotional distress (3.63, p = <.001), lower 
GAF symptom (md = 9.16, p < .001) and disability scores 
(md = 8.88, p < .001). Furthermore, the de novo group 
scored higher on the PANSS positive subscale (md = 2.52, 
p = .046) and lower on the GAF disability subscale 
(md = 6.90, p = .021) compared to the remission group. 
All significant group differences between the remission and 
no-OCS group diminished except for a remaining higher 
score on the emotional distress subscale (md = 2.00, 
p = .009).
Comparable analyses in siblings revealed significant 
results for all CAPE subscales at baseline and follow-
up (Table 3). Post hoc analyses at baseline showed sig-
nificantly higher scores of the OCS remission and de 
novo group on CAPE positive (md: 4.63, p < .001; md: 
2.22, p = .015), negative (md: 5.37, p < .001; md: 2.09, 
Table 2  Between-group differences in PANSS and GAF scores at baseline and 3-year follow-up in patients
PANSS Positive and Negative Syndrome Scale, GAF General Assessment of Functioning, OCS obsessive–compulsive symptoms
OCS de novo OCS remission Persistent OCS No-OCS Between-group differences
N = 72 N = 70 N = 45 N = 415 MANCOVA
Baseline
PANSS
 Positive scale 14.6 ± 6.4 15.6 ± 6.4 16.8 ± 6.7 12.2 ± 5.9 F3,594 = 11.647, p < .001
 Negative scale 15.0 ± 6.0 15.0 ± 6.6 17.1 ± 6.1 14.1 ± 6.3 F3,594 = 4.450, p = .004
 Emotional distress 17.0 ± 5.3 18.1 ± 5.8 19.0 ± 5.9 14.3 ± 5.2 F3,594 = 18.523, p < .001
GAF
 Symptoms 54.4 ± 15.5 50.2 ± 17.4 51.4 ± 15.4 58.6 ± 15.6 F3,576 = 7.537, p < .001
 Disability 55.4 ± 14.7 52.7 ± 15.3 48.6 ± 14.2 57.2 ± 15.5 F3,576 = 5.709, p = .001
Follow-up
PANSS
 Positive scale 14.6 ± 6.0 12.0 ± 6.4 15.9 ± 6.4 10.9 ± 5.3 F3,595 = 14.746, p < .001
 Negative scale 13.2 ± 4.8 12.2 ± 4.6 14.6 ± 6.5 12.4 ± 5.6 F3,595 = 2.603, p = .051
 Emotional distress 16.2 ± 4.6 14.5 ± 5.4 17.9 ± 6.1 12.5 ± 4.6 F3,595 = 24.363, p < .001
GAF
 Symptoms 52.8 ± 16.1 59.2 ± 16.3 51.1 ± 13.1 62.0 ± 15.8 F3,562 = 11.518, p < .001
 Disability 54.2 ± 14.7 61.7 ± 14.5 50.0 ± 11.9 62.9 ± 16.1 F3,562 = 13.912, p < .001
Table 3  Between-group 
differences in CAPE scores at 
baseline and 3-year follow-up 
in siblings
CAPE Community Assessment of Psychic Experiences, OCS obsessive–compulsive symptoms
OCS de novo OCS remission No-OCS Between-group differences
N = 25 N = 26 N = 601 MANOVA
Baseline
CAPE
 Positive 6.4 ± 4.7 8.8 ± 9.4 4.1 ± 4.1 F2,649 = 15.800, p < .001
 Negative 9.8 ± 4.7 13.1 ± 7.8 7.7 ± 5.0 F2,649 = 15.476, p < .001
 Depressive 6.7 ± 3.1 8.4 ± 5.5 5.1 ± 2.9 F2,649 = 18.282, p < .001
Follow-up
CAPE
 Positive 5.8 ± 9.8 5.5 ± 8.1 2.2 ± 3.2 F2,649 = 17.981, p < .001
 Negative 11.7 ± 7.2 11.5 ± 8.3 6.4 ± 5.6 F2,649 = 19.345, p < .001
 Depressive 6.6 ± 4.2 7.0 ± 5.2 3.9 ± 3.1 F2,649 = 19.030, p < .001
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p = .004) and depressive symptoms (md: 3.36, p < .001; 
md: 1.62, p = .009) when compared to the no-OCS. The 
remission group also scored higher on all three outcome 
variables when compared to the de novo OCS group (md: 
2.40, p = .05; md: 1.74, p = .040; md: 3.27, p = .022). 
Three years later, the remission and de novo groups still 
scored significantly higher on all CAPE subscales com-
pared to the no-OCS group (positive: md: 3.29, p < .001; 
md: 3.63, p < .001; negative: md: 5.12, p < .001; md: 
5.34, p < .001; depressive: md: 3.10, p < .001; md: 2.75, 
p < .001), but all differences between the remission and de 
novo group diminished.
The longitudinal course of OCS and associated changes 
in psychopathology and general functioning
To analyse the course of symptom severity and the impact 
of change versus stability in OCS over time, we subse-
quently calculated separate repeated measure ANOVAs for 
the de novo group versus remission group and persistent 
group versus no-OCS group within the patient sample.
Comparisons between the de novo group and the remis-
sion group showed significant group x time interaction 
effects for the PANSS positive (F1,140 = 9.986, p = .002) 
and emotional distress scores (F1,140 = 8.323, p = .005), as 
well as for GAF symptoms (F1,129 = 9.915, p = .002) and 
disabilities (F1,129 = 11.850, p = .001).
Subsequent group-specific post hoc paired t tests 
showed significant symptom reduction over time within 
the remission group for the positive (T69 = 4.533, 
p < .001, dz = −.54), negative (T69 = 3.390, p = .001, 
dz = −.41) and emotional distress (T69 = 4.805, p < .001, 
dz = −.33) subscale of the PANSS. Analyses further 
revealed significant improvement in GAF scores (symp-
toms: T63 = −3.299, p = .002, dz = −.41; disability: 
T63 = −3.745, p < .001, dz = −.47).
Within the de novo group post hoc paired t tests showed 
no significant changes over time, except for significant 
symptom reductions in the PANSS negative subscale 
(T71 = 2.683, p = .009, dz = −.32). The within-group 
changes in patients are shown in Fig. 1a.
On a dimensional level changes in YBOCS severity cor-
related significantly with changes in the PANSS positive 
subscale (r = .22, p = .009), the PANSS emotional dis-
tress scale (r = .20, p = .018) and the two GAF subscales 
symptoms (r = −.24, p = .006) and distress (r = −.25, 
p = .004).
Equivalent analyses were performed within the sample 
of unaffected siblings. The repeated measure ANOVA com-
paring participants with OCS in remission to those with de 
novo occurrence showed one significant group × time inter-
action effect for the CAPE depressive scale (F1,49 = 6.375, 
p = .015) and a significant time effect for the positive 
subscale (F1,49 = 4.321, p = .043). Post hoc paired t tests 
revealed significant reduction in subclinical positive symp-
toms (T25 = 2.805, p = .010, dz = −.55) and depressive 
symptoms (T25 = 2.060, p = .050, dz = −.40) within the 
OCS-remission group. Paired analyses within the de novo 
group again showed no significant changes in these vari-
ables, but a trend for increased CAPE negative symptoms 
(T24 = −2.018, p = .055, dz = .40). The within-group 
changes in siblings are shown in Fig. 1b. Regarding cor-
relations between change scores, we found significant asso-
ciations between changes in YBOCS severity and changes 
in all three CAPE subscales (positive: r = .37, p = .008; 
negative: r = .33, p = .017; depressive: r = .30, p = .030).
In addition to the comparisons between groups, which 
showed changes in reported OCS, we analysed between-
group differences in patients reporting either persistent 
OCS or no-OCS. Repeated measure ANOVAs, with ill-
ness duration as covariate, showed significant group effects 
for all three PANSS subscales (positive: F1,453 = 34.167, 
p < .001; negative: F1,453 = 12.252, p = .001; emotional 
distress: F1,453 = 53.511, p < .001) and time effects for the 
PANSS negative (F1,453 = 20.830, p < .001) and emotional 
distress subscale (F1,453 = 7.345, p = .007). No signifi-
cant interaction effects were observed. Analyses of the two 
GAF scales also revealed significant group effects (symp-
toms: F1,424 = 18.887, p < .001; disability: F1,424 = 24.814, 
p < .001) and a significant time effect for the disabil-
ity subscale (F1,424 = 13.079, p < .001). Subsequent post 
hoc paired t tests showed significant improvement in all 
reported variables within the no-OCS group (positive: 
T425 = 4.450, p < .001, dz = −.22, negative: T425 = 5.532, 
p < .001, dz = −.26, emotional distress: T425 = 6.404, 
p < .001, dz = −.33, GAF symptoms: T384 = −3.484, 
p = .001, dz = −.19, and GAF disability: T384 = −5.964, 
p < .001, dz = −.34), whereas we did not observe any sig-
nificant changes within the persistent OCS group, except 
for a significant reduction in the PANSS negative subscale 
(T44 = 2.801, p = .008, dz = −.38).
Discussion
A fair number of studies assessed the association between 
co-occurring OCS, psychotic symptoms and social func-
tioning in patients with schizophrenia. However, results 
have been inconsistent and until now little is known about 
the longitudinal course and interaction of these vari-
ables [18]. In accordance with a prospective study of the 
5-year course of comorbid OCS in a cohort of first-episode 
patients [10], only a minority of our patients reported per-
sistent OCS and the majority reported variation in course 
as either remission or de novo occurrence of OCS in 
3 years.
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In line with our first hypothesis, the presence of comor-
bid OCS was associated with higher severity in schizophre-
nia-related symptom clusters and with more impairment in 
social and vocational functioning. Patients, who reported 
OCS at least once during the assessment period, reported 
more positive symptoms and emotional distress as well as 
lower overall functioning when OCS were present, com-
pared to the no-OCS group. In addition, a significant group 
effect in the repeated measure analyses showed that these 
associations remained stable over time in patients suffering 
from persistent comorbid OCS. Interestingly, we found 
similar results within the groups of unaffected siblings. 
Siblings showed higher scores in subclinical positive and 
depressive symptoms when experiencing OCS compared to 
those who either never reported OCS or did not experience 
OCS at the time of assessment.
Regarding the hypothesized association between 
changes in OCS and changes in severity of other symp-
toms, repeated measure analyses and post hoc compari-
sons revealed that the remission group in patients showed 
Fig. 1  Cohen’s dz effect sizes 
for within-group changes in 
patients and siblings. The 
figures show standardized mean 
differences for within-group 
changes over time referred to 
as Cohen’s dz. 0 indicates no 
change in outcome measures 
between baseline and follow-
up; − indicates decrease in 
symptoms/distress; + indicates 
increase in symptoms/dis-
tress. *p < 0.05, **p < 0.005, 
***p < 0.001
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significant decrease in positive and negative symptoms and 
emotional distress and improvement in the level of func-
tioning over time. However, contrary to expectations, the 
de novo group did not report significant increase in these 
variables over time, but rather already reported higher 
scores in positive symptoms and emotional distress at base-
line compared to the no-OCS group. Similar results were 
found in siblings, with the remission group showing signifi-
cant reduction in subclinical positive and depressive symp-
toms. Siblings in the de novo group showed a trend for an 
increase in negative symptoms, but again already reported 
more subclinical positive, negative and depressive symp-
toms prior to the presence of OCS.
Our results suggest a more severe clinical picture for 
individuals suffering from both schizophrenia and OCS, 
supporting previous findings, which consistently reported 
more depressive symptoms and more impairment in social 
and vocational functioning [10, 18, 24]. The increased 
severity of emotional distress when OCS were present is 
not surprising given that depressive symptoms have been 
found associated with all co-occurring anxiety disorders 
in psychotic disorders [42] and the fact that depression is 
the most common comorbid disorder in OCD individuals 
[43]. Noteworthy, higher severity of emotional distress was 
already present at baseline in patients and siblings report-
ing de novo OCS 3 years later. Rickelt et al. [44] recently 
investigated the reciprocal influence between obsessive–
compulsive and depressive symptoms in OCD patients and 
found that depressive symptoms at baseline predicted OCS 
severity 1 year later. According to their hypothesis, rumi-
nation, worries and doubt, which frequently go along with 
emotional distress and are strongly related to obsessive 
thoughts, might be associated with a subsequent attempt to 
reduce resulting anxiety through compulsive behaviour.
Furthermore, analyses revealed that the presence of OCS 
was consistently associated with more positive symptoms 
in patients and on a subclinical level in siblings. These 
results stand in line with the meta-analytic conclusion 
by Cunill et al. [14]. However, results contradict earlier 
studies, which did not find an association, including the 
repeated investigation of a large first-episode sample [10]. 
In line with earlier assumptions, we suggest that the het-
erogeneity in findings might result not only from differ-
ences in study designs, but also from differences in sam-
ple characteristics regarding symptom severity and illness 
duration [14]. Our findings stress the importance to account 
for changes in symptom clusters, because in line with the 
study by de Haan et al. [10] initial OCS were not neces-
sarily associated with more psychotic symptoms in the 
future. Regarding the association with negative symptoms, 
findings were inconclusive. We only found significantly 
higher severity of negative symptoms in the patient group 
reporting persistent OCS at baseline, but these decreased 
over time. Similarly, negative symptoms slightly decreased 
in the de novo patients group, but increased on a subclini-
cal level in siblings. Further subgroup analyses might elu-
cidate possible interrelations between OCS and negative 
symptoms. Lysaker, for example, only found more negative 
symptoms in a subsample of comorbid OCS patients with 
poorer functioning and more cognitive impairment [15].
The more consistent link between comorbid OCS and 
positive symptoms in our sample raises the question of cau-
sality. It has been suggested that the association between 
co-occurring OCS and greater severity of psychotic symp-
toms could simply be an artefact of the phenomenological 
overlap of the two disorders [14]. Distinguishing obses-
sions and compulsions from delusions and hallucina-
tions is indeed a diagnostic challenge, if patients show 
poor insight into their obsessions or display compulsions 
that resemble stereotypic mannerisms [45, 46]. However, 
assuming symptom overlap, we would expect simultaneous 
changes within our alternating groups, but only observed 
a decrease in psychotic symptoms in the remission group 
and no changes in the de novo group. Furthermore, the reli-
ably identification of comorbid OCS with the YBOCS in 
patients with schizophrenia has been shown [35, 36]. It is 
therefore unlikely that diagnostic artefacts explain our find-
ings and the significant co-occurrence observed between 
the two disorders in general.
So far, attempts to elucidate possible pathophysiologi-
cal mechanisms of the co-occurrence of OCD and schizo-
phrenia have been inconclusive and suggest multicausal 
pathways for different subgroups [47]. Increasing evidence 
suggests a shared genetic vulnerability based on familial 
aggregation of schizophrenia–spectrum disorders and OCD 
[4, 48]. Our exploratory analyses do not support the notion 
of an increased relative risk for siblings to experience OCS 
if their sibling(patient) belongs to one of the OCS groups. 
However, these analyses are limited by small sample sizes 
resulting in large confidence intervals and have to be inter-
preted with great cautious. Furthermore, common neurobi-
ological mechanisms have been proposed to underlie both 
obsessive–compulsive and psychotic disorders and may 
explain the high percentage of their co-occurrence [49, 50]. 
Neuroimaging studies describe abnormalities of the frontal 
lobe, the basal ganglia, the thalamus and the cerebellum in 
both schizophrenia and OCD [49] and have identified dis-
sociated prefrontal cortex connection with the basal ganglia 
in both conditions [51, 52]. In more detail, evidence sug-
gests a particular “prefrontal” dysfunction in schizophrenia 
and “orbitofrontal” dysfunctions in OCD patients [53].
The heterogeneous clinical presentation of comorbid 
OCS with symptom changes in the majority of our sample 
suggests more than a shared genetic and/or neurobiological 
vulnerability. The observed association between symptom 
remission might reflect an interaction between symptom 
Eur Arch Psychiatry Clin Neurosci 
1 3
clusters, which functionally influence each other [54]. 
Another possibility is that the course of symptoms over 
time is influenced by individual and environmental factors. 
Increased sensitivity to stress, negative affectivity and dys-
functional coping have, for example, been shown to con-
stitute key components underlying both symptoms of OCD 
[55, 56] and psychosis [57, 58]. Recent investigations sug-
gest that these mechanisms might also be crucial determi-
nants of their co-occurrence [7, 59]. As briefly mentioned 
above, pre-existing higher emotional distress in the two 
de novo groups could possibly mirror heightened levels of 
anxiety and stress sensitivity.
Furthermore, the development of de novo OCS under 
antipsychotic medication, especially clozapine, has been 
increasingly acknowledged [60, 61]. Considering this 
effect within our data, more patients in the de novo and per-
sistent groups were treated with clozapine when compared 
to individuals in the no-OCS group. Because clozapine is 
the treatment of choice in treatment-resistant symptoms, 
it might also explain why patients in the de novo group 
reported higher severity of psychotic symptoms before 
OCS onset.
Due to the observational nature of our study, the discus-
sion of possible mechanisms remains speculative. We are 
well aware that assessing OCS only twice over the 3-year 
period is a main limitation of our study and precludes 
answering questions of causality. To further unravel the 
time course and possible co-variation between changes in 
psychotic, affective and obsessive–compulsive symptoms, 
and investigate underlying effect of individual and environ-
mental factors such as stress sensitivity, coping skills and 
medication, prospective investigations with more frequent 
assessments are needed.
We acknowledge further limitations: We tried to account 
for relevant differences in age of onset and illness duration 
between our groups by including these variables as covari-
ates in our analyses. However, we cannot completely rule 
out that higher severity and persistence of psychotic symp-
toms in our persistent OCS group is partly due to a more 
chronic and severe course of schizophrenia, independent 
of co-occurring OCS. Furthermore, because reliable infor-
mation on the current intake of antipsychotic and antide-
pressant medication was only available in a subsample of 
our study, we did not account for cross-sectional between-
group differences in our analyses. However, we did not find 
differences in treatment or illness duration between the two 
groups reporting changes in OCS, and significant associa-
tions between the presence of OCS and severity of sub-
clinical psychotic symptoms in siblings strongly suggest 
that the link between the two conditions is more than just 
a medication effect. We further acknowledge that the mean 
severity of OCS in our groups was relatively low due to the 
fact that patients with relevant, although mild OCS were 
included in the OCS groups. Hence, compared to patient 
groups with more severe OCS, our results might underesti-
mate associations with other clinical variables and the level 
of functioning.
In conclusion, our results suggest that the presence of 
at least mild co-occurring OCS is associated with greater 
severity of psychotic and affective symptoms and indicates 
lower levels of overall social and vocational functioning 
and additional burden for the affected patients, especially 
when OCS persist over time. The remission or absence 
of OCS on the other hand is associated with an improve-
ment in psychotic and affective symptoms, respectively, 
and strengthens the need for a better understanding of the 
co-occurrence of OCS with other symptoms and clini-
cal research aimed to develop and test treatment options. 
Comparable associations in a sample of non-psychotic drug 
naive siblings support the view that associations between 
OCS and symptom dimensions of schizophrenia are at least 
partly unrelated to treatment effects.
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